Compare AbCellera Biologics Inc (ABCL) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs IQIYI Inc - ADR — how do they compare? AbCellera Biologics Inc trades at $9.52 (market cap $2.99B), while IQIYI Inc - ADR trades at $1.37 (market cap $1.30B). The key difference: AbCellera Biologics Inc is far larger — about 2.3× IQIYI Inc - ADR's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals.
| ABCL | IQ | |
|---|---|---|
Market Cap | $2.99B | $1.30B |
Sector | Health | Media |
52-Week High | $9.76 | $2.79 |
52-Week Low | $2.78 | $0.96 |
Enterprise Value | $2.58B | $2.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
iQIYI (IQ) trades at $1.36, up 2.26% today, with a bullish technical signal from moving averages. The company reported a net loss of $206.31 million in 2025, with revenue declining to $27.29 billion. Valuation ratios show a high P/E of 144.05 but attractive P/S of 0.33 and P/B of 0.67. Recent news highlights AI platform growth and leadership changes, with Q2 2026 earnings due August 18, 2026.
The outlook is mixed: analyst consensus is 50% buy, but profitability challenges and revenue declines pose risks. Upside potential exists from AI initiatives and cost controls, yet competitive pressures and regulatory uncertainty in China remain headwinds. The stock offers speculative value for turnaround bets, balanced by fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
